Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.

Clarke JM; Morse MA; Lyerly HK; Clay T; Osada T

首页> 外文期刊>Expert opinion on biological therapy >Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.

【24h】

Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.

机译：针对表达WT1的肿瘤的腺病毒疫苗免疫疗法。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IMPORTANCE OF THE FIELD: Tumor associated antigens (TAAs) offer specific targets for developing cancer immunotherapies. In particular, viral vectors encoding transgenic TAAs have been used in recent vaccination strategies. Wilm's Tumor gene (WT1) is a robust TAA which is overexpressed in many malignancies and has been recently used to develop a novel recombinant adenovirus (Ad-WT1) for antitumor immunotherapy. AREAS COVERED IN THIS REVIEW: The lines of evidence over the past two decades leading to the development of Ad-WT1 immunotherapy are reviewed, including preclinical studies and clinical trials using WT1-based vaccines and TAA-expressing adenoviral vectors for antitumor therapy. WHAT THE READER WILL GAIN: The fundamental immunogenic properties of WT1-based vaccines are detailed, as well as the recent progress in using adenoviral vectors for eliciting a TAA-specific immune response. The reader will also gain an understanding of the evidence supporting Ad-WT1 antitumor therapy in vivo. TAKE HOME MESSAGE: Ad-WT1 elicits a potent CD4(+) and CD8(+) T cell immune response and can effectively inhibit tumor growth in vivo, thus making it an important potential cancer therapy worthy of future investigation.

机译：领域的重要性：肿瘤相关抗原（TAA）为开发癌症免疫疗法提供了特异性靶标。特别地，在最近的疫苗接种策略中已经使用了编码转基因TAA的病毒载体。威尔姆肿瘤基因（WT1）是一种强大的TAA，在许多恶性肿瘤中均过表达，最近已用于开发新型重组腺病毒（Ad-WT1）进行抗肿瘤免疫治疗。综述中涉及的领域：回顾了过去二十年来导致Ad-WT1免疫治疗发展的证据，包括临床前研究和使用基于WT1的疫苗和表达TAA的腺病毒载体进行抗肿瘤治疗的临床试验。读者将获得什么：详细介绍了基于WT1的疫苗的基本免疫原性，以及使用腺病毒载体引发TAA特异性免疫应答的最新进展。读者还将了解支持Ad-WT1体内抗肿瘤治疗的证据。温馨提示：Ad-WT1引发有效的CD4（+）和CD8（+）T细胞免疫反应，可以有效抑制体内肿瘤的生长，因此使其成为重要的潜在癌症治疗方法，值得进一步研究。

著录项

来源
《Expert opinion on biological therapy》 |2010年第6期|共9页
作者
Clarke JM; Morse MA; Lyerly HK; Clay T; Osada T;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. [J] . Clarke JM, Morse MA, Lyerly HK, Expert opinion on biological therapy . 2010,第6期

机译：针对表达WT1的肿瘤的腺病毒疫苗免疫疗法。
2. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. [J] . Xia D, Moyana T, Xiang J Cell research. . 2006,第3期

机译：组合腺病毒介导的基因治疗和树突状细胞疫苗可对抗公认的肿瘤。
3. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. [J] . Xia D, Moyana T, Xiang J Cell Research . 2006,第3期

机译：组合腺病毒介导的基因治疗和树突状细胞疫苗可对抗公认的肿瘤。
4. TARGETED IMMUNOTHERAPY- THE USE OF DENDRITIC CELLS IN ANTI-TUMOR VACCINES [C] . G.A.P Hospers, J van Zanten, N.H. Mulder, International Symposium on Blood Transfusion . 2000

机译：靶向免疫疗法 - 使用树突状细胞在抗肿瘤疫苗中的使用
5. CD40-targeted adenovirus as an anti-tumor vaccine [D] . Mody, Disha 2008

机译：靶向CD40的腺病毒作为抗肿瘤疫苗
6. Induction of Wilms’ tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine [O] . Takuya Osada, Christopher Y. Woo, Matthew McKinney, -1

机译：使用截短的WT1表达腺病毒疫苗诱导Wilms肿瘤蛋白（WT1）的特异性抗肿瘤免疫力
7. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer [O] . Jim Xiang, Yue Chen, Terence Moyana 2000

机译：具有工程肿瘤疫苗和腺病毒介导的基因转移的建立肿瘤的组合免疫疗法
8. Targeted Tumor Therapy by Use of Recombinant Adenovirus Vectors That Selectively Replicate in Hypoxic Regions of Tumors. [R] . Li, C. Y., Huang, Q., Dewhirst, M. W. 2003

机译：通过使用在肿瘤的缺氧区域中选择性复制的重组腺病毒载体进行靶向肿瘤治疗。

Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.

摘要

著录项

相似文献

相关主题

期刊订阅